BCRX Stock saw the intraday high of $13.595 and lowest of $12.6501 per share. BioCryst Pharmaceuticals, Inc. has a P/E ratio of 0, compared to Zoetis Inc Cl A’s 45.24 and Takeda Pharmaceutical CO Ltd’s 23.25. Zero analysts have issued estimates for Rocket Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.57) and the highest estimate coming in at ($0.44). All Rights Reserved. © 2021 CNBC LLC. Item 7.01. The Durham, North Carolina-based company said … BioCryst Pharmaceuticals Announces R&D Day. Find the latest Idera Pharmaceuticals, Inc. (IDRA) stock discussion in Yahoo Finance's forum. On March 18, 2021, following a meeting with the Committee for Orphan Medicinal Products, which is the European Medicines Agency's ("EMA") committee responsible for recommending orphan designation of medicines for rare diseases, BioCryst Pharmaceuticals, Inc. (the "Company") withdrew its application for orphan medicinal product … Global Business and Financial News, Stock Quotes, and Market Data and Analysis. Blackrock Inc. is the largest shareholder of the company, while 209 institutions own stock in it. News about Biocryst Pharmaceuticals Inc., including commentary and archival articles published in The New York Times. BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is adding to the gains the stock experienced yesterday after issuing a press release announcing that … Also during today’s trading, the S&P 500 Index has surged 0.1%, while the Dow Jones Industrial also saw a negative seesion, down -0.42% today. We’re developing novel oral medicines for rare diseases to help patients take part in the everyday activities they enjoy. RESEARCH TRIANGLE PARK, N.C., March 15, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the company will host a virtual R&D day on Monday, March 22, 2021 from 9:00 am to 11:00 am ET. Sign up for free newsletters and get more CNBC delivered to your inbox. Got a confidential news tip? We are a collection of passionate individuals united by a commitment to scientific excellence and an unwavering focus on the needs of patients. Data is a real-time snapshot *Data is delayed at least 15 minutes. California Compliance Program Declaration. Share your opinion and gain insight from other stock traders and investors. BioCryst Pharmaceuticals, Inc. insiders own 0.85% of total outstanding shares while institutional holders control 73.95%, with the float percentage being 74.58%. [not verified in body] Baldino served as Cephalon's chairman and chief executive officer, [not verified in body] until his death in December 2010. BioCryst to Host Virtual R&D Day on March 22, 2021. In a press release issued early Monday morning, BioCryst Pharmaceuticals said it will host a virtual R&D day on … BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s Biggest Investors. RESEARCH TRIANGLE PARK, N.C., March 15, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today … Find the latest Institutional Holdings data for BioCryst Pharmaceuticals, Inc. Common Stock (BCRX) at Nasdaq.com. Real time BioCryst Pharmaceuticals (BCRX) stock price quote, stock graph, news & analysis. View the latest BioCryst Pharmaceuticals Inc. (BCRX) stock price, news, historical charts, analyst ratings and financial information from WSJ. We are developing a pipeline of oral drugs for rare diseases, including our next generation kallikrein inhibitor for hereditary angioedema (HAE). A Division of NBCUniversal. Stay up to date with the latest discoveries, events, and reports from BioCryst. The Company focuses on the treatment of rare diseases. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. BioCryst Pharmaceuticals, Inc. is a biotechnology company. BioCryst Pharmaceuticals, Inc. (BCRX) Quote Overview » News » BioCryst Pharmaceuticals, Inc. (BCRX) Zacks News Zacks News BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Misses Revenue Estimates BioCryst Pharmaceuticals, Inc. is a biotechnology company. BioCryst Pharmaceuticals Inc. stock is now 70.34% up from its year-to-date (YTD) trading value. Wall Street brokerages expect Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) to announce earnings per share (EPS) of ($0.52) for the current quarter, Zacks reports. We combine traditional cell biology with medicinal chemistry to build synthetic compounds that bind to specific protein targets to fight disease. We want to hear from you. BioCryst Pharmaceuticals Inc. had a pretty favorable run when it comes to the market performance. BioCryst Pharmaceuticals, Inc. Common Stock (BCRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. BioCryst’s core development programs include: BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases BioCryst to Host Virtual R&D Day on March 22, 2021 March 11, 2021 Early Access to BioCryst’s Berotralstat Granted for HAE Patients in France March 2, 2021 BioCryst Submits Marketing Authorization Application for UK Approval of ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema The program will cover BioCryst's unique, proven and prolific approach to developing oral medicines for rare diseases, with a focus on BCX9930, an oral Factor D … Rocket Pharmaceuticals reported earnings of ($0.39) per […] DURHAM, N.C. (AP) — BioCryst Pharmaceuticals Inc. (BCRX) on Thursday reported a loss of $60.5 million in its fourth quarter. The company’s 52-week high price is 13.93, which means current price is +74.55% above from all time high which was touched on 03/15/21. Find the latest BioCryst Pharmaceuticals, Inc. (BCRX) stock quote, history, news and other vital information to help you with your stock trading and investing. The... BioCryst appoints Helen Thackray chief research and development officer, Biocryst’s berotralstat granted early access for HAE in France, BioCryst Pharmaceuticals (BCRX) Presents At Cowen 41st Annual Healthcare Virtual Conference - Slideshow, BioCryst's ORLADEYO nabs CHMP positive recommendation in hereditary angioedema. Find the latest news headlines from BioCryst Pharmaceuticals, Inc. Common Stock (BCRX) at Nasdaq.com. BioCryst Pharmaceuticals Inc. (BCRX) full year performance was 643.43% Get this delivered to your inbox, and more info about our products and services. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. Zacks Investment Research upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) from a sell rating to a hold rating in a report issued on Monday, Zacks.com reports.. Get the latest news and real-time alerts from BioCryst Pharmaceuticals, Inc. (BCRX) stock at Seeking Alpha. BioCryst Pharmaceuticals Inc. BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the development and discovery of novel, oral, and small-molecule medicines. ©2021 BioCryst Pharmaceuticals, Inc. All rights reserved. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The 1-year high price for the company’s stock is recorded $13.93 on 03/15/21, with the lowest value was $7.27 for the same time period, recorded on 01/05/21. BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Regulation FD Disclosure. There is no recent news for this security. Cephalon, Inc. was an American biopharmaceutical company co-founded in 1987 by pharmacologist Frank Baldino, Jr., neuroscientist Michael Lewis, and organic chemist James C. Kauer—all three former scientists with the DuPont Company. According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular …